AR111459A1 - PEPTIDES AND COMBINATIONS OF THE SAME FOR USE IN AN IMMUNOTHERAPY AGAINST CANCER - Google Patents

PEPTIDES AND COMBINATIONS OF THE SAME FOR USE IN AN IMMUNOTHERAPY AGAINST CANCER

Info

Publication number
AR111459A1
AR111459A1 ARP180100893A ARP180100893A AR111459A1 AR 111459 A1 AR111459 A1 AR 111459A1 AR P180100893 A ARP180100893 A AR P180100893A AR P180100893 A ARP180100893 A AR P180100893A AR 111459 A1 AR111459 A1 AR 111459A1
Authority
AR
Argentina
Prior art keywords
peptides
tumors
combinations
same
against cancer
Prior art date
Application number
ARP180100893A
Other languages
Spanish (es)
Inventor
Sebastian Haen
Annika Nelde
Nico Trautwein
Marco Moreno Di
Markus Lffler
Daniel Kowalewski
Juliane Sarah Walz
Stefan Stevanovic
Hans-Georg Rammensee
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of AR111459A1 publication Critical patent/AR111459A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

Péptidos, proteínas, ácido nucleicos y células de utilidad en métodos inmunoterapéuticos. En particular, la presente acta se relaciona con inmunoterapias contra el cáncer. Se relaciona además con epitopes de péptidos de células T asociados a tumores, solos o en combinación con otros péptidos asociados a tumores que pueden servir, por ejemplo, como ingredientes farmacéuticos activos en composiciones de vacunas que estimulan respuestas inmunológicas anti-tumorales o para estimular células T ex vivo y transferirlas a los pacientes. Los péptidos unidos a moléculas del complejo mayor de histocompatibilidad (MHC), o péptidos semejantes, también pueden ser blancos de anticuerpos, receptores de células T solubles y otras moléculas de unión.Peptides, proteins, nucleic acids and cells useful in immunotherapeutic methods. In particular, this act is related to cancer immunotherapies. It also relates to epitopes of T-cell peptides associated with tumors, alone or in combination with other peptides associated with tumors that can serve, for example, as active pharmaceutical ingredients in vaccine compositions that stimulate anti-tumor immune responses or to stimulate cells. T ex vivo and transfer them to patients. Peptides bound to major histocompatibility complex (MHC) molecules, or similar peptides, can also be targets of antibodies, soluble T cell receptors and other binding molecules.

ARP180100893A 2017-04-10 2018-04-10 PEPTIDES AND COMBINATIONS OF THE SAME FOR USE IN AN IMMUNOTHERAPY AGAINST CANCER AR111459A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762483702P 2017-04-10 2017-04-10

Publications (1)

Publication Number Publication Date
AR111459A1 true AR111459A1 (en) 2019-07-17

Family

ID=67439454

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100893A AR111459A1 (en) 2017-04-10 2018-04-10 PEPTIDES AND COMBINATIONS OF THE SAME FOR USE IN AN IMMUNOTHERAPY AGAINST CANCER

Country Status (2)

Country Link
AR (1) AR111459A1 (en)
EA (2) EA202191120A3 (en)

Also Published As

Publication number Publication date
EA202191120A2 (en) 2021-08-31
EA201992417A1 (en) 2020-02-20
EA202191120A3 (en) 2022-01-31

Similar Documents

Publication Publication Date Title
CL2023001346A1 (en) Use of peptides in immunotherapy against small cell lung cancer and others.
CO2018010284A2 (en) Treatments against uterine cancer
PE20230768A1 (en) NOVEL PEPTIDES AND NEW PEPTIDE COMBINATIONS FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING SMALL CELL LUNG CANCER AND OTHER CANCERS
CR20180398A (en) PEPTIDES, COMBINATIONS OF PEPTIDES AND CELLS FOR USE IN IMMUNOTHERAPY AGAINST BLADDER CANCER AND OTHER TYPES OF CANCER
CR20180422A (en) PEPTIDES AND COMBINATION OF NOVELED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TUMORS (2017-0522 Division)
CO2019008008A2 (en) New peptides and new peptide combinations for use in immunotherapy against ovarian and other cancers
CL2020002123A1 (en) Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancer.
CL2021000979A1 (en) New peptides and peptide combinations for use in immunotherapy against esophageal and other cancers. (divisional application no. 201703361)
CO2019012077A2 (en) Peptides and combinations thereof for use in immunotherapy against various types of cancer
CO2021000534A2 (en) Immunotherapy with b * 07-restricted peptides and a combination of anticancer peptides and related methods
CO2017009922A2 (en) Peptides and combination of peptides for immunotherapy against various tumors
CL2024000530A1 (en) Peptides and combinations, their use in immunotherapy against lung cancer and other cancers
CO2019012071A2 (en) Peptides and peptide combinations for use in immunotherapy against leukemia and other cancers
CO2021003404A2 (en) Immunotherapy with a * 01-restricted peptides and a combination of anticancer peptides and related methods
CL2023001324A1 (en) Peptides, combinations, cells for immunotherapy against bladder cancer and other cancers
AR112331A1 (en) PEPTIDES AND PEPTID COMBINATIONS FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS
CL2020002935A1 (en) Peptides for use in cancer immunotherapy
CL2021001336A1 (en) Immunotherapy with b * 08 restricted peptides and a combination of anticancer peptides and related methods
CO2017009101A2 (en) Peptides and peptide combination
CL2017002766A1 (en) New peptides and new combinations of peptides and supports for use in immunotherapy against colorectal carcinoma and other cancers
AR111459A1 (en) PEPTIDES AND COMBINATIONS OF THE SAME FOR USE IN AN IMMUNOTHERAPY AGAINST CANCER
AR111370A1 (en) PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPIES AGAINST LEUKEMIA AND OTHER CANCER
AR124243A2 (en) PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL AND OTHER CANCERS
AR117437A1 (en) IMMUNOTHERAPY WITH PEPTIDES RESTRICTED TO B * 08 AND A COMBINATION OF PEPTIDES AGAINST CANCER AND RELATED METHODS
AR115881A1 (en) IMMUNOTHERAPY WITH PEPTIDES RESTRICTED TO B * 07 AND A COMBINATION OF PEPTIDES AGAINST CANCER AND RELATED METHODS